Arcutis Biotherapeutics, Inc. (ARQT)
23.66
-0.19
(-0.80%)
USD |
NASDAQ |
Sep 03, 16:00
23.70
+0.04
(+0.17%)
Pre-Market: 09:09
Arcutis Biotherapeutics Cash from Investing (Quarterly) : -15.22M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -15.22M |
| March 31, 2026 | -11.33M |
| December 31, 2025 | -34.18M |
| September 30, 2025 | -25.25M |
| June 30, 2025 | 17.42M |
| March 31, 2025 | 11.75M |
| December 31, 2024 | 34.88M |
| September 30, 2024 | 84.78M |
| June 30, 2024 | -62.14M |
| March 31, 2024 | -28.70M |
| December 31, 2023 | -62.19M |
| September 30, 2023 | 45.55M |
| June 30, 2023 | 89.12M |
| March 31, 2023 | 107.75M |
| December 31, 2022 | 42.20M |
| September 30, 2022 | -197.26M |
| Date | Value |
|---|---|
| June 30, 2022 | 52.56M |
| March 31, 2022 | 15.30M |
| December 31, 2021 | 23.50M |
| September 30, 2021 | 3.471M |
| June 30, 2021 | -164.92M |
| March 31, 2021 | 62.00M |
| December 31, 2020 | -75.89M |
| September 30, 2020 | -91.71M |
| June 30, 2020 | 6.105M |
| March 31, 2020 | -20.33M |
| December 31, 2019 | -36.00M |
| September 30, 2019 | 21.18M |
| June 30, 2019 | -2.241M |
| March 31, 2019 | -9.27M |
| December 31, 2018 | -11.53M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | -8.529M |
| Insmed, Inc. | 24.51M |
| Emergent BioSolutions, Inc. | -52.30M |
| Exelixis, Inc. | 91.43M |
| Vertex Pharmaceuticals, Inc. | -45.80M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 12.64M |
| Cash from Financing (Quarterly) | 1.99M |
| Free Cash Flow | 39.15M |
| Free Cash Flow Per Share (Quarterly) | 0.0918 |
| Free Cash Flow to Equity (Quarterly) | 13.02M |
| Free Cash Flow to Firm (Quarterly) | 15.86M |
| Free Cash Flow Yield | 1.24% |